3,144 results match your criteria Antiphospholipid Antibody Syndrome and Pregnancy

Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature.

Semin Thromb Hemost 2021 Jun 15. Epub 2021 Jun 15.

Section of Clinical Biochemistry, University of Verona, Verona, Italy.

The term "lupus anticoagulant (LA)" identifies a form of antiphospholipid antibodies (aPLs) causing prolongation of clotting tests in a phospholipid concentration-dependent manner. LA is one of the laboratory criteria identified in patients with antiphospholipid (antibody) syndrome (APS). The presence of LA in patients with APS represents a significant risk factor for both thrombosis and pregnancy morbidity. Read More

View Article and Full-Text PDF

Arterial Dissection in Antiphospholipid Syndrome Patients: Two Case Reports and a Literature Review.

Eur J Case Rep Intern Med 2021 24;8(5):002610. Epub 2021 May 24.

Department Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.

Antiphospholipid syndrome (APS) is a multisystemic autoimmune disease which presents with thromboembolic disease, pregnancy complications and the presence of antiphospholipid antibodies. There are some reports of arterial dissections in different sites of the body associated with APS. We describe two patients with APS who developed ischaemic stroke as a result of vertebral artery dissection in the absence of acquired and genetic risk factors for arterial dissection. Read More

View Article and Full-Text PDF

Anti-beta 2 glycoprotein 1 domain IgA positive antiphospholipid syndrome secondary to incomplete Behcet's disease: a case report.

Ann Palliat Med 2021 Jun 8. Epub 2021 Jun 8.

Department of Rheumatology, the First Hospital of Hebei Medical University, Shijiazhuang, China.

Antiphospholipid syndrome (APS) is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis, and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity. APS is induced by persistent positive antiphospholipid antibodies (aPL), the main being lupus anticoagulant (LA), and/or anticardiolipin (aCL) antibodies, and/or anti-beta 2 glycoprotein 1 (β2-GP1) antibodies. Some studies have shown that the incidence of APS is about 5 new cases per 100,000 persons per year, and the prevalence is around 40-50 cases per 100,000 persons. Read More

View Article and Full-Text PDF

[Antiphospholipid syndrome: diagnosis and management].

Masahiro Ieko

Rinsho Ketsueki 2021 ;62(5):445-455

Department of Hematology and Clinical Laboratory, Iwate Prefectural Chubu Hospital.

Antiphospholipid syndrome (APS) is an acquired thrombophilia associated with autoimmunity and is a syndrome that should always be considered when examining patients with thrombosis and pregnancy complications. As per the Sydney criteria, a diagnosis can be established with at least one clinical finding, such as arteriovenous thrombosis and the presence of at least one of the antiphospholipid antibodies (aPL), such as anticardiolipin antibodies (aCL). Moreover, phosphatidylserine-dependent anti-prothrombin antibody and anti-b2GPI-domain 1 antibody are correlated with APS manifestations and enable APS diagnosis. Read More

View Article and Full-Text PDF

Anti-vimentin/cardiolipin IgA in the Antiphospholipid Syndrome: a new tool for "seronegative" diagnosis.

Clin Exp Immunol 2021 Jun 9. Epub 2021 Jun 9.

Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder defined by the simultaneous presence of vascular clinical events, pregnancy morbidity and antiphospholipid antibodies (aPL). In clinical practice it is possible to find patients with APS who are persistently negative for the routine aPL tests ("seronegative APS", SN-APS). Recently, the identification of aPL IgA and/or anti-β2-GPI IgA was shown to represent a further test in SN-APS patients. Read More

View Article and Full-Text PDF

Obstetric Antiphospholipid Syndrome: An Approach from Glycans of the Immunoglobulin G.

J Hum Reprod Sci 2021 Jan-Mar;14(1):97-100. Epub 2021 Mar 30.

Department of Microbiology and Parasitology, School of Medicine, Reproduction Group, University of Antioquia, Medellín, Colombia.

This is a case report of women with pregnancy morbidity (PM), some of them associated with antiphospholipid syndrome (APS), in which the glycan patterns of immunoglobulin G (IgG) were investigated based on the theory of alteration of glycosylation in autoimmunity. We used lectin blot to determine changes in terminal glycosylation of polyclonal IgG from women with antiphospholipid (aPL) antibodies and PM plus vascular thrombosis (PM/VT) and seronegative-obstetric APS (SN-OAPS). In addition, we analyzed IgG from women with PM without aPL (PM/aPL-) and healthy women, as controls. Read More

View Article and Full-Text PDF

Practical Considerations and Testing Nuances for the Detection of Lupus Anticoagulant.

Am J Clin Pathol 2021 Jun 2. Epub 2021 Jun 2.

Department of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.

Objectives: Lupus anticoagulant (LA) detection requires (1) prolongation of a phospholipid (PL)-dependent clot-based screening assay, (2) noncorrection upon adding normal pooled plasma, and (3) a confirmatory PL dependency test. Paired LA assays run screening and confirmatory tests simultaneously, with their test ratio (TR) or differences used to evaluate test results. We evaluated patients whose paired testing demonstrated PL dependence suggestive of LA, yet the low PL screen was not prolonged. Read More

View Article and Full-Text PDF

Structural Imaging Characteristic, Clinical Features and Risk Factors of Cerebral Venous Sinus Thrombosis: A Prospective Cross-Sectional Analysis from a Tertiary Care Hospital in Pakistan.

Diagnostics (Basel) 2021 May 26;11(6). Epub 2021 May 26.

Department of Neurology, King Edward Medical University, Lahore 54000, Pakistan.

Cerebral venous sinus thrombosis (CVST) is a rare cause of stroke that accounts for 0.5-1.0% of all strokes. Read More

View Article and Full-Text PDF

Anti-Phosphatidylserine/Prothrombin Antibodies in Healthy Women with Unexplained Recurrent Pregnancy Loss.

J Clin Med 2021 May 13;10(10). Epub 2021 May 13.

Department of Immunology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.

Recurrent pregnancy loss (RPL) affects up to 6% of couples. Although chromosomal aberrations of the embryos are considered the leading cause, 50% of cases remain unexplained. Antiphospholipid Syndrome is a known cause in a few cases. Read More

View Article and Full-Text PDF

POTS and Antiphospholipid Syndrome: An Unlikely Association.

Case Rep Rheumatol 2021 4;2021:9942668. Epub 2021 May 4.

Rocky Vista University, Parker, CO, USA.

Antiphospholipid syndrome is a rare complication of postural orthostatic tachycardia syndrome. Clinically, the presentation has overlapping symptoms of both diseases, with lightheadedness or syncope when moving from a supine to a standing position as well as blood clots, headache, or pregnancy complications in women. This case presentation involves a 39-year-old patient identified as female who has been diagnosed with POTS and elevated anticardiolipin antibodies. Read More

View Article and Full-Text PDF

Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.

J Matern Fetal Neonatal Med 2021 May 27:1-8. Epub 2021 May 27.

The First I.M. Sechenov Moscow State Medical University (Sechenov University), Moscow, Russia.

Background: The current recommended therapy of obstetric antiphospholipid syndrome (APS) is a long-term anticoagulant therapy that affects the final event, namely, when the thrombosis has already occurred. Unfortunately, this schedule is not always effective and fails despite the correct risk stratification and an adequate adjusted dose.

Materials And Methods: From 2013 to 2020 we observed 217 women with antiphospholipid antibodies and obstetric morbidities who were treated with conventional treatment protocol (aspirin low doses ± LMWH). Read More

View Article and Full-Text PDF

Exosome-Contained APOH Associated With Antiphospholipid Syndrome.

Front Immunol 2021 4;12:604222. Epub 2021 May 4.

Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.

Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disease that can lead to thrombosis and/or pregnancy complications. Exosomes, membrane-encapsulated vesicles that are released into the extracellular environment by many types of cells, can carry signals to recipient cells to affect angiogenesis, apoptosis, and inflammation. There is increasing evidence suggesting that exosomes play critical roles in pregnancy. Read More

View Article and Full-Text PDF

Deciphered coagulation profile to diagnose the antiphospholipid syndrome using artificial intelligence.

Thromb Res 2021 Jul 15;203:142-151. Epub 2021 May 15.

Department of Data Analysis and Artificial Intelligence, Synapse Research Institute, Maastricht, the Netherlands; Department of Functional Coagulation, Synapse Research Institute, Maastricht, the Netherlands.

The antiphospholipid syndrome (APS) is diagnosed by the presence of lupus anticoagulant and/or antibodies against cardiolipin or β-glycoprotein-1 and the occurrence of thrombosis or pregnancy morbidity. The assessment of overall coagulation is known to differ in APS patients compared to normal subjects. The accelerated production of key factor thrombin causes a prothrombotic state in APS patients, and the reduced efficacy of the activated protein C pathway promotes this effect. Read More

View Article and Full-Text PDF

Characteristics of purified Anti-β2GPI IgG N-glycosylation associate with thrombotic, obstetric, and catastrophic antiphospholipid syndrome.

Rheumatology (Oxford) 2021 May 20. Epub 2021 May 20.

Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Second Road, Shanghai, 200025, China.

Objective: Anti-β-2 glycoprotein I (anti-β2GPI) antibodies, defined as primary pathogenic antibody in antiphospholipid syndrome (APS). It has been reported that IgG Fc N-glycosylation affects IgG effector, we aim to investigate the association of Fc glycosylation profiles of purified anti-β2GP1 IgG with clinical features of APS.

Methods: We purify anti-β2GPI IgG and total IgG from 82 APS patients including 9 catastrophic antiphospholipid syndrome (CAPS) patients, as well as total IgG from 103 healthy controls to quantitatively analyze all detectable Fc N-glycanforms of all IgG subclasses with Multiple Reaction Monitoring (MRM) method based on UPLC-ESI-QqQ mass spectrometry. Read More

View Article and Full-Text PDF

[Neurological Manifestations in Antiphospholipid Syndrome].

Brain Nerve 2021 May;73(5):526-536

Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University.

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by persistent presence of positive antiphospholipid antibodies (aPLs). Historically, aPLs first attracted attention at the beginning of the 1970s, as a risk factor for the development of myelitis via cross-reaction with cephalin and sphingomyelin as neuronal tissue-enriched phospholipids. Primary APS manifestations include arteriovenous thrombosis and pregnancy complications; however, in rare cases, aPL-related neurological disorders including cognitive dysfunction, chorea, and transverse myelitis are observed. Read More

View Article and Full-Text PDF

Early ADAMTS13 testing associates with pre-eclampsia occurrence in antiphospholipid syndrome.

Thromb Res 2021 Jul 27;203:101-109. Epub 2021 Apr 27.

Department of Gynaecology and Obstetrics, First Moscow State Medical University (Sechenov University), Russian Federation; Department of Haematology, CHU Nîmes, Univ Montpellier, Nîmes, France; Faculty of Pharmaceutical and Biological Sciences, Montpellier University, Montpellier, France; UA 011 INSERM- Université de Montpellier, Institut Desbrest d'Epidémiologie et de Santé Publique, Montpellier, France. Electronic address:

Introduction: Women with obstetric antiphospholipid syndrome (oAPS) still develop placental diseases, mainly pre-eclampsia (PEcl), which diagnosis is associated with reduced ADAMTS13 levels. Testing ADAMTS13 in newly pregnant oAPS may provide evidence for risk stratification.

Materials And Methods: We retrospectively investigated the prognostic value of ADAMTS13 activity, antigen and antibodies on stored plasma samples obtained prior to beginning low-molecular weight heparin-low dose aspirin treatment in 513 oAPS women. Read More

View Article and Full-Text PDF

Value of second-trimester uterine artery pulsatility index in pregnancies with systemic lupus erythematosus and/or antiphospholipid syndrome.

J Matern Fetal Neonatal Med 2021 May 12:1-7. Epub 2021 May 12.

Department of Obstetrics and Gynecology, Hospital General de Granollers, Barcelona, Spain.

Objective: To assess the value of the second trimester mean pulsatility index of the uterine arteries (MPI-UtA) to predict adverse perinatal outcome (APO) in women with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS).

Methods: Pregnancies with either an SLE diagnosis or with primary APS controlled at our Hospital during a 10 years period were included. MPI-UtA was performed between 19-23 weeks' gestation. Read More

View Article and Full-Text PDF

Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome.

Lupus Sci Med 2021 May;8(1)

Nephrology, Leiden University Medical Center, Leiden, The Netherlands.

Objectives: SLE and/or antiphospholipid syndrome (SLE/APS) are complex and rare systemic autoimmune diseases that predominantly affect women of childbearing age. Women with SLE/APS are at high risk of developing complications during pregnancy. Therefore, clinical practice guidelines recommend that patients with SLE/APS should receive multidisciplinary counselling before getting pregnant. Read More

View Article and Full-Text PDF

Antiphospholipid antibodies levels and potential effects on in-vitro fertilization in a large cohort of infertile Syrian women.

Ann Med Surg (Lond) 2021 May 18;65:102301. Epub 2021 Apr 18.

Assisted Reproductive Unit, Oriental Hospital, Damascus, Syria.

Background: Obstetric morbidities represent a common hallmark manifestation of antiphospholipid syndrome (APS), with the recurrent loss of pregnancy as the main complication. The presence of antiphospholipid antibodies (APA) and its potential impact have not been established yet in infertile women seeking assisted reproduction technologies in Syria.This study aims to determine the prevalence of anticardiolipin antibodies (aCL) and lupus anticoagulation (LAC) and their association with age and the In vitro fertilization (IVF) outcomes in a large sample of Syrian women. Read More

View Article and Full-Text PDF

Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients.

Arthritis Res Ther 2021 05 4;23(1):134. Epub 2021 May 4.

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.

Background: The criteria for antiphospholipid syndrome (APS) include severe preeclampsia and/or placental insufficiency leading to preterm delivery before 34 weeks of gestation, but this APS manifestation has been rarely studied. Thus, we report a series of severe preeclampsia occurred in patients with APS.

Methods: We retrospectively analysed data of women with APS (Sydney criteria) who experienced severe preeclampsia with delivery before 34 weeks' gestation between 2000 and 2017 at five French internal medicine departments and one Italian rheumatology unit. Read More

View Article and Full-Text PDF

Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome.

Semin Thromb Hemost 2021 Apr 30. Epub 2021 Apr 30.

Grupo Reproducción, Departamento Microbiología y Parasitología, Facultad de Medicina, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia.

Antiphospholipid syndrome is an autoimmune disease characterized by the persistent presence of antiphospholipid antibodies, along with occurrence of vascular thrombosis and pregnancy morbidity. The variety of antiphospholipid antibodies and their related mechanisms, as well as the behavior of disease in wide groups of patients, have led some authors to propose a differentiation of this syndrome into two independent entities: vascular and obstetric antiphospholipid syndrome. Thus, previous studies have discussed whether specific autoantibodies may be responsible for this differentiation or, in contrast, how the same antibodies are able to generate two different clinical presentations. Read More

View Article and Full-Text PDF

Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges.

Int J Mol Sci 2021 Apr 28;22(9). Epub 2021 Apr 28.

Department of Rheumatology, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia.

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thromboembolism, obstetric complications, and the presence of antiphospholipid antibodies (aPL). Extracellular vesicles (EVs) play a key role in intercellular communication and connectivity and are known to be involved in endothelial and vascular pathologies. Despite well-characterized in vitro and in vivo models of APS pathology, the field of EVs remains largely unexplored. Read More

View Article and Full-Text PDF

Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome.

Molecules 2021 Apr 24;26(9). Epub 2021 Apr 24.

Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the production of β2-glycoprotein I (β2GPI)-dependent autoantibodies, with vascular thrombosis or obstetrical complications. Around 20% of APS patients are refractory to current treatments. Crassolide, a cembranoid diterpene extracted from soft corals, is a potential therapeutic candidate. Read More

View Article and Full-Text PDF

Aspirin Desensitization: Implications for Acetylsalicylic Acid-Sensitive Pregnant Women.

Medicina (Kaunas) 2021 Apr 17;57(4). Epub 2021 Apr 17.

Department of Obstetrics and Gynecology, CUF Descobertas Hospital, 1998-018 Lisbon, Portugal.

Low-dose acetylsalicylic acid (ASA) is widely used during pregnancy to prevent obstetric complications of placental dysfunction, such as preeclampsia, stillbirth and fetal growth restriction, and obstetric complications in pregnant women with antiphospholipid syndrome. ASA-sensitive pregnant women cannot benefit from the effects of ASA due to the possibility of severe or potentially life-threatening hypersensitivity reactions to ASA. ASA desensitization is a valuable and safe therapeutic option for these women, allowing them to start daily prophylaxis with ASA and prevent pregnancy complications. Read More

View Article and Full-Text PDF

VWF, Platelets and the Antiphospholipid Syndrome.

Int J Mol Sci 2021 Apr 18;22(8). Epub 2021 Apr 18.

Department of Functional Coagulation, Synapse Research Institute, 6217KM Maastricht, The Netherlands.

The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). Laboratory criteria for the classification of APS include the detection of lupus anticoagulant (LAC), anti-cardiolipin (aCL) antibodies and anti-β2glycoprotein I (aβ2GPI) antibodies. Clinical criteria for the classification of thrombotic APS include venous and arterial thrombosis, along with microvascular thrombosis. Read More

View Article and Full-Text PDF

Multidisciplinary Unit Improves Pregnancy Outcomes in Women with Rheumatic Diseases and Hereditary Thrombophilias: An Observational Study.

J Clin Med 2021 Apr 3;10(7). Epub 2021 Apr 3.

Department of Nursing, Faculty of Health Sciences, University of Jaén, 23003 Jaén, Spain.

Rheumatic diseases (RD) and hereditary thrombophilias (HT) can be associated with high-risk pregnancies. This study describes obstetric outcomes after receiving medical care at a multidisciplinary consultation (MC) and compares adverse neonatal outcomes (ANOs) before and after medical care at an MC. This study is a retrospective observational study among pregnant women with RD and HT treated at an MC of a university hospital (southern Spain) from 2012 to 2018. Read More

View Article and Full-Text PDF

[Triple negative breast cancer, repeated abortions and severe digital ischemia].

Medicina (B Aires) 2021 ;81(2):289-292

Direccción, Instituto de Oncología ángel H. Roffo, Universidad de Buenos Aires, Argentina.

The present case corresponds to a woman with history of three miscarrieges less than10 weeks and breast cancer, who develops severe digital ischemia after the second cycle of capecitabine. Positive antiphospholipid antibodies were determined. Patients with obstetric antiphospholipid syndrome have an increased risk of developing cancer, and severe digital ischemia could be an unusual form of presentation of the antiphospholipid syndrome in patients with cancer. Read More

View Article and Full-Text PDF

Is Lupus Nephritis a Prognosis Factor for Pregnancy? Maternal and Foetal Outcomes.

Reumatol Clin (Engl Ed) 2021 Apr 21. Epub 2021 Apr 21.

Hospital Materno Neonatal de la Provincia de Córdoba, Córdoba, Argentina; Hospital Córdoba, Córdoba, Argentina; Cátedra de Semiología, Hospital Córdoba, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina. Electronic address:

Background: Pregnancy in women with systemic lupus erythematosus (SLE) and nephritis (LN) is at risk of foetal and maternal complications.

Objective: To evaluate the effect of LN on pregnancy with respect to foetal and maternal outcome.

Methods: We retrospectively studied all pregnant SLE patients with and without diagnosis of LN, who attended the Materno Neonatal Hospital in Cordoba city, Argentina, from January 2015 to April 2017. Read More

View Article and Full-Text PDF

Risk factors for pregnancy morbidity in women with antiphospholipid syndrome.

J Reprod Immunol 2021 06 29;145:103315. Epub 2021 Mar 29.

Obstetrics and Gynecology Department, Peking University People's Hospital, Beijing, China. Electronic address:

Antiphospholipid syndrome (APS) increases the risk of obstetric complications, but risk factors for pregnancy morbidity in women with APS remain incompletely characterized. This retrospective study included pregnant women with APS and a control group without APS admitted to Peking University People's Hospital between January 2013 and September 2019. Clinical data were extracted from medical records. Read More

View Article and Full-Text PDF

An Observational Study to Evaluate the Effectiveness of Rivaroxaban in the Management of Cerebral Venous Sinus Thrombosis.

Cureus 2021 Mar 3;13(3):e13663. Epub 2021 Mar 3.

Neurology, Jinnah Medical College Hospital, Karachi, PAK.

Background and objectives Cerebral venous sinus thrombosis (CVST) is a relatively rare and underdiagnosed type of stroke. Rivaroxaban is licensed for venous thromboembolism in patients opting for elective knee and hip replacement surgeries, preventing pulmonary embolism and precluding stroke and systemic embolism in sufferers of non-valvular atrial fibrillation. Beneficial outcomes depicting the efficacious role of rivaroxaban in treating CVST are under study. Read More

View Article and Full-Text PDF